Bachet, J., Chibaudel, B., Bonnetain, F., Validire, P., Hammel, P., André, T., & Louvet, C. (2015). A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: The AFUGEM GERCOR trial. BMC Cancer.
Citação norma ChicagoBachet, Jean-Baptiste, Benoist Chibaudel, Franck Bonnetain, Pierre Validire, Pascal Hammel, Thierry André, and Christophe Louvet. "A Randomized Phase II Study of Weekly Nab-paclitaxel Plus Gemcitabine or Simplified LV5FU2 As First-line Therapy in Patients With Metastatic Pancreatic Cancer: The AFUGEM GERCOR Trial." BMC Cancer 2015.
MLA citiranjeBachet, Jean-Baptiste, et al. "A Randomized Phase II Study of Weekly Nab-paclitaxel Plus Gemcitabine or Simplified LV5FU2 As First-line Therapy in Patients With Metastatic Pancreatic Cancer: The AFUGEM GERCOR Trial." BMC Cancer 2015.